Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-Modality Imaging and Correlative Studies in Patients With Leukemia
NCT03422731Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Feb 2018
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluorothymidine F-18 in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 cohorts), sponsored by City of Hope. Primary endpoints: Change over time in cellularity and adiposity, Change over time of red marrow (cellularity) and yellow marrow (adipocyte) up to 2 years and 4 more. Started Feb 2018; status: active, not recruiting.
02
Drugs
fluorothymidine F-18
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03422731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422731.